Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said